Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2026OncoOpen Access

Epigenetic Reprogramming in Cancer Metastasis: From Histone Modifications to Therapeutic Vulnerabilities

View Full Paper
Ask AI
Bookmark
Share

Authors

PPPrashant PandeyBabasaheb Bhimrao Ambedkar UniversityDTDevika TripathiPushpawati Singhania Research InstituteKMKartik MittalBabasaheb Bhimrao Ambedkar University

Discussion

Loading...

Member takes

Implication

Review details epigenetic mechanisms affecting metastasis, evaluates therapies, and suggests strategies for better outcomes.

Key Points

  • To understand the epigenetic mechanisms of cancer metastasis and their therapeutic implications.
  • Reviewed literature on epigenetic regulations in cancer metastasis including histone modifications and DNA methylation.
  • Evaluated the role of therapeutic inhibitors targeting epigenetic regulators like HDAC, EZH2, and LSD1.
  • Discussed circulating tumor DNA methylation as biomarkers for metastatic risk.
  • Epigenetic changes are crucial in promoting cancer cell invasiveness and immune evasion.
  • Therapeutic inhibitors for HDAC and EZH2 show promise in preclinical studies, with some in clinical trials.
  • Long non-coding RNAs, like HOTAIR, reinforce metastatic characteristics in tumor cells.

Cite This Study

Pandey et al. (2026) studied this question.

synapsesocial.com/papers/6a758c2e847ab6d26c0200c5https://doi.org/10.3390/onco6030040
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1LSD1 modulates the bone metastasis of breast cancer cells through hnRNPA2B1-mediated sorting of exosomal miRNAs2024 · 18 citations
  2. 2How ATP-Dependent Chromatin Remodeling Complexes Regulate Vertebrate Embryonic Development2026 · 8 citations
  3. 3Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.2024 · 4 citations
  4. 4Epigenetic regulation in cancer metastasis2026 · 1 citations
  5. 5αvβ3 Integrin and Folate-Targeted pH-Sensitive Liposomes with Dual Ligand Modification for Metastatic Breast Cancer Treatment2024 · 36 citations